Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome-Reference-Cited by-同舟云学术

Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome

Published:2015-04-29 Issue:11 Volume:90 Page:1091-1092
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Jain Preetesh¹,Verstovsek Srdan¹,Loghavi Sanam²,Jorgensen Jeffrey L.²,Patel Keyur P.²,Estrov Zeev¹,Fayad Luis³,Pemmaraju Naveen¹

Affiliation:

1. Department of Leukemia; The University of Texas, M.D. Anderson Cancer Center; Houston Texas

2. Departments of; Hematopathology, The University of Texas, M.D. Anderson Cancer Center; Houston Texas

3. Lymphoma and Myeloma; The University of Texas, M.D. Anderson Cancer Center; Houston Texas

Funder

University of Texas MD Anderson Cancer Center

Publisher

Wiley

Subject

Hematology

Reference5 articles.

1. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study;Tefferi;J Clin Oncol,2011

2. [thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly];Takai;Rinsho Ketsueki,2010

3. Castleman-kojima disease (TAFRO syndrome): A novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of fukushima (6 june, 2012) and nagoya meetings (22 september, 2012);Kawabata;J Clin Exp Hematop,2013

4. Successful treatment of a patient with multicentric castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody;Kawabata;Intern Med,2013

5. Successful treatment of a caucasian case of multifocal castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report;Tedesco;Exp Hematol Oncol,2015

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TAFRO syndrome associated with C3 nephropathy (an analysis of clinical experience);The Clinician;2024-01-19

2. The experience of diagnosis and treatment for TAFRO syndrome;Annals of Hematology;2023-09-15

3. TAFRO syndrome: A disease that known is half cured;Hematological Oncology;2022-10-03

4. International definition of iMCD-TAFRO: future perspectives;Journal of Clinical and Experimental Hematopathology;2022

5. TAFRO syndrome presenting as intrahepatic cholangitis on autopsy;Clinical Case Reports;2021-03-03